Abstract:Background: Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and second leading cause of cancer-related deaths worldwide. The heightened mortality associated with HCC is largely attributed to its propensity for metastasis, which cannot be achieved without remodeling or loss of the basement membrane (BM). Despite advancements in targeted therapies and immunotherapies, resistance and limited efficacy in late-stage HCC underscore the urgent need for better therapeutic options and early diagnostic biomarkers. Our study aimed to address these gaps by investigating and evaluating potential biomarkers to improve survival outcomes and treatment efficacy in patients with HCC. Method: In this study, we collected the transcriptome sequencing, clinical, and mutation data of 424 patients with HCC from The Cancer Genome Atlas (TCGA) and 240 from the International Cancer Genome Consortium (ICGC) databases. We then constructed and validated a prognostic model based on metastasis and basement membrane-related genes (MBRGs) using univariate and multivariate Cox regression analyses. Five immune-related algorithms (CIBERSORT, QUANTISEQ, MCP counter, ssGSEA, and TIMER) were then utilized to examine the immune landscape and activity across high- and low-risk groups. We also analyzed Tumor Mutation Burden (TMB) values, Tumor Immune Dysfunction and Exclusion (TIDE) scores, mutation frequency, and immune checkpoint gene expression to evaluate immune treatment sensitivity. We analyzed integrin subunit alpha 3 (ITGA3) expression in HCC by performing single-cell RNA sequencing (scRNA-seq) analysis using the TISCH 2.0 database. Lastly, wound healing and transwell assays were conducted to elucidate the role of ITGA3 in tumor metastasis. Results: Patients with HCC were categorized into high- and low-risk groups based on the median values, with higher risk scores indicating worse overall survival. Five immune-related algorithms revealed that the abundance of immune cells, particularly T cells, was greater in the high-risk group than in the low-risk group. The high-risk group also exhibited a higher TMB value, mutation frequency, and immune checkpoint gene expression and a lower tumor TIDE score, suggesting the potential for better immunotherapy outcomes. Additionally, scRNA-seq analysis revealed higher ITGA3 expression in tumor cells compared with normal hepatocytes. Wound healing scratch and transwell cell migration assays revealed that overexpression of the MBRG ITGA3 enhanced migration of HCC HepG2 cells. Conclusion: This study established a direct molecular correlation between metastasis and BM, encompassing clinical features, tumor microenvironment, and immune response, thereby offering valuable insights for predicting clinical outcomes and immunotherapy responses in HCC.

Galectin-3 favours tumour metastasis via the activation of β-catenin signalling in hepatocellular carcinoma

LncRNA AY promotes hepatocellular carcinoma metastasis by stimulating ITGAV transcription.

Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK|[sol]|PI3K|[sol]|AKT signaling

Galectin-1 induces hepatocellular carcinoma EMT and sorafenib resistance by activating FAK/PI3K/AKT signaling

Integrated Stable Isotope Labeling by Amino Acids in Cell Culture (SILAC) and Isobaric Tags for Relative and Absolute Quantitation (itraq) Quantitative Proteomic Analysis Identifies Galectin-1 As a Potential Biomarker for Predicting Sorafenib Resistance in Liver Cancer*

RNF219/ α ‐Catenin/LGALS3 Axis Promotes Hepatocellular Carcinoma Bone Metastasis and Associated Skeletal Complications

Galectin-9 acts as a prognostic factor with antimetastatic potential in hepatocellular carcinoma.

Galectin-3 induces protein ezrin phosphorylation via integrin α3β1/c-src/PI3K/AKT cascade and promotes cervical cancer metastasis

TGM3 Promotes Epithelial-Mesenchymal Transition and Hepatocellular Carcinogenesis and Predicts Poor Prognosis for Patients after Curative Resection.

Expression of Galectin-1 in Carcinoma-Associated Fibroblasts Promotes Gastric Cancer Cell Invasion Through Upregulation of Integrin Beta 1

Endogenous and Exogenous Galectin-3 Promote the Adhesion of Tumor Cells with Low Expression of MUC1 to HUVECs Through Upregulation of N-cadherin and CD44

Downregulation of Galectin-3 Causes A Decrease in Upar Levels and Inhibits the Proliferation, Migration and Invasion of Hepatocellular Carcinoma Cells

ST6GALNAC4 Promotes Hepatocellular Carcinogenesis by Inducing Abnormal Glycosylation.

Galectin‐3 enhances trastuzumab resistance by regulating cancer malignancy and stemness in HER2‐positive breast cancer cells

Galectin-3 Induces Protein Ezrin Phosphorylation Via Integrin Alpha 3 Ss 1/C-Src/Pi3k/Akt Cascade And Promotes Cervical Cancer Metastasis

Glypican-3 Promotes Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Cells Through Erk Signaling Pathway

METTL3 and STAT3 form a positive feedback loop to promote cell metastasis in hepatocellular carcinoma

Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis

Prognostic and Diagnostic Significance of Galectins in Pancreatic Cancer: a Systematic Review and Meta-Analysis

Metastasis and basement membrane-related signature enhances hepatocellular carcinoma prognosis and diagnosis by integrating single-cell RNA sequencing analysis and immune microenvironment assessment

Role of the Interaction Between Galectin-3 and Cell Adhesion Molecules in Cancer Metastasis